What does this research mean for the field?

Optimized dose-escalation regimens for incretin mimetics in type 2 diabetes increase tolerance for nausea and vomiting, enabling the use of higher doses that enhance therapeutic effectiveness. Novelty: ClaimNovelty.CONFIRMATORY. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aims to evaluate the effects of dose-escalation regimens on tolerance to nausea and vomiting in patients with type 2 diabetes receiving incretin mimetics.

March 1, 20261 citations

Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.

View Full Paper

MNM. NauckUniversitätsmedizin Greifswald VPViktoria PunovSt. Josef-Hospital YKYu KangChinese Academy of Medical Sciences & Peking Union Medical College

Key Points

The study aims to evaluate the effects of dose-escalation regimens on tolerance to nausea and vomiting in patients with type 2 diabetes receiving incretin mimetics.
Examined dose-escalation regimens for incretin mimetics
Assessed changes in nausea and vomiting tolerance
Correlated higher doses with therapeutic effectiveness
Optimized regimens resulted in greater tolerance for nausea and vomiting
Higher doses were associated with increased treatment effectiveness

Abstract

Taken together, optimised dose-escalation regimens may lead to greater tolerance for nausea and vomiting, which allows to use of higher doses, which are associated with greater therapeutic effectiveness.

Perguntar à IA

Bookmark

View Full Paper

Perguntar à IA

Bookmark

View Full Paper

Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting.

Key Points

Abstract

Cite This Study

Also Consider

Also Consider